The 7M share plan increase is virtually certain to pass given CEO voting control. Monitor the pace of equity grants post-approval and any associated S-8 filings. The company's cash burn rate and need for capital suggest further dilutive financing is likely.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 13 $2.70entry
- T+1 · 6d ago −3.70%α −1.79% · $2.60
- T+5 · 2d ago −17.41%α −8.85% · $2.23
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sunshine Biopharma's 2026 proxy statement seeks shareholder approval to increase the 2023 Equity Incentive Plan share reserve from 3,415 to 7,000,000 shares, a massive 2,050x increase. The company has no shares remaining under the plan, and the CEO holds 130,000 Series B Preferred shares with 1,000 votes each, giving him effective control over all voting matters. The company has sustained net losses of $5.98M in 2025, $5.13M in 2024, and $4.51M in 2023, with zero total shareholder return over three years.
Key Facts
- Proposal to increase 2023 Equity Incentive Plan shares from 3,415 to 7,000,000 shares (a 2,050x increase)
- CEO Dr. Steve Slilaty holds 130,000 Series B Preferred shares with 1,000 votes each, giving him 130 million votes vs. 823,772 common shares outstanding
- No shares currently available under the 2023 Plan; all 3,415 previously authorized shares were issued to one director in 2026
- Net losses: ($5,975,352) in 2025, ($5,134,116) in 2024, ($4,506,044) in 2023
- Total shareholder return of $0 on a $100 investment over three years (three reverse stock splits totaling ~400,000-fold reduction)
- CEO 2025 total compensation: $465,953; CEO severance upon termination without cause: $14 million
- Three 5%+ holders: Intracoastal Capital (9.99%), CVI Investments (9.3%), BJI Financial Group (5.6%)
- Auditor changed from Bush & Associates to M&K CPAS in September 2025
Financial Impact
Proposed 7,000,000 share increase represents 850% dilution relative to 823,772 common shares outstanding; CEO controls 130 million votes via Series B Preferred, ensuring passage
Risk Factors
- Massive potential dilution of 850% from the equity plan increase
- CEO has unilateral voting control over all proposals via Series B Preferred stock
- Sustained net losses with no path to profitability disclosed
- Three reverse stock splits in three years indicate Nasdaq compliance challenges
- CEO's $14 million severance clause creates a significant contingent liability
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001683168-26-008615 |
| Document: 0001683168-26-008615-index-headers.html | 0001683168-26-008615 |
| Document: 0001683168-26-008615-index.html | 0001683168-26-008615 |
| Document: 0001683168-26-008615.txt | 0001683168-26-008615 |
Track record
15 reports on SBFM
6 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +69.19% at T+20 after the Oct 8, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 18, 20263d ago S-1 Bearish 6/10 Entry $2.35 Now $2.23 +5.11% settles Nov 27
- Nov 13, 20268d ago DEFA14A Bearish 5/10 Entry $2.60 Now $2.23 +14.23% settles Nov 23
- Nov 12, 20269d ago DEF 14A Bearish 5/10 Viewing Entry $2.70 to $2.23 Now $2.23 +17.41% ▲ +17.41% +8.85% vs SPY
- Nov 10, 202611d ago SC 13G/A Neutral 2/10 Entry $2.75 to $2.41 Now $2.23 −18.91% ▼ −12.36% −8.47% vs SPY
- Oct 14, 20265w ago SC 13G Neutral 3/10 Entry $0.2430 to $0.2154 Now $2.23 +817.70% ▼ −11.36% −11.81% vs SPY
- Oct 13, 20265w ago SC 13G Neutral 4/10 Entry $0.2430 to $0.2154 Now $2.23 +817.70% ▼ −11.36% −11.81% vs SPY
- Oct 9, 20266w ago 8-K Bearish 6/10 Entry $0.3020 to $0.2418 Now $2.23 −638.41% ▲ +19.93% +18.44% vs SPY
- Oct 9, 20266w ago 424B4 Bearish 7/10 Entry $0.3020 to $0.2418 Now $2.23 −638.41% ▲ +19.93% +18.44% vs SPY
- Oct 8, 20266w ago EFFECT Bearish 6/10 Entry $8.60 to $4.60 Now $2.23 +74.07% ▲ +46.51% +46.24% vs SPY
- Oct 5, 20266w ago SC 13G/A Bearish 5/10 Entry $0.3979 to $0.2363 Now $2.23 −460.44% ▲ +40.61% +40.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers